GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (NAS:CALT) » Definitions » Short-Term Debt

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Short-Term Debt : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Calliditas Therapeutics AB Short-Term Debt?

Calliditas Therapeutics AB's Short-Term Debt for the quarter that ended in Dec. 2023 was $0.00 Mil.


Calliditas Therapeutics AB Short-Term Debt Historical Data

The historical data trend for Calliditas Therapeutics AB's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB Short-Term Debt Chart

Calliditas Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only - - - - -

Calliditas Therapeutics AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Calliditas Therapeutics AB Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Calliditas Therapeutics AB Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Calliditas Therapeutics AB's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description

Traded in Other Exchanges
Address
Kungsbron 1, D5, Stockholm, SWE, SE-111 22
Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.